BLK vs LYEL · P/E 27, rev $24.22B vs rev $6.0K
BlackRock Inc (BLK) versus Lyell Immunopharma Inc (LYEL) — a side-by-side from cached financials, not a winner call.
BlackRock Inc (BLK) is a asset management company listed on NYSE. It is led by Larry Fink.
Lyell Immunopharma Inc (LYEL) is a biotechnology company listed on US.
Latest reported BLK revenue for 2025-12-31 was $24.22B. Net income was $5.55B. Revenue was up 89.3% from 2024-12-31 to 2025-12-31. BLK currently screens at market cap $172.19B and trailing P/E 26.6.
Latest reported LYEL revenue for 2026-06-30 was $6.0K. Net income was -$68.9M. LYEL currently screens at market cap $143.5M.
BLK currently screens at market cap $172.19B and trailing P/E 26.6. LYEL currently screens at market cap $143.5M.
Not investment advice. Open the BLK and LYEL stock pages for the full models.
Not investment advice.